Skip to content
Review Open access

The CREM–IL-15 axis: decoding the persistence–exhaustion paradox in NK cell immunotherapy

Aug 2026 · Cancer Immunology and Immunotherapy · Vol 75 · 0 citations · 237 references
Medicine

TL;DR

In CAR-NK models, Rafei further demonstrated in CAR-NK models that CREM functions as a regulatory checkpoint limiting NK cell cytotoxicity and cytokine production, while its relevance in resting/native NK cells remains to be established.

Abstract

Natural killer (NK) cells are critical components of the innate immune system, renowned for their ability to recognize and eliminate malignant and infected cells without prior sensitization. NK cell immunotherapy encompasses various approaches, including adoptive transfer of ex vivo expanded NK cells, cytokine stimulation to enhance their activity, and genetic modifications to improve persistence and specificity. CREM is a cAMP-responsive transcription factor that modulates gene expression in response to receptor- and cytokine-driven signaling. Recent evidence now shows that IL-15 and CAR stimulation rapidly induce CREM in activated NK cells. Rafei (Nature 643:1076–1086, 2025) further demonstrated in CAR-NK models that CREM functions as a regulatory checkpoint limiting NK cell cytotoxicity and cytokine production, while its relevance in resting/native NK cells remains to be established. The CREM–IL-15 signaling axis has emerged as a pivotal regulator of NK cell biology, influencing their development, activation, and longevity. IL-15 is a critical cytokine for NK cell survival, proliferation, and functional maturation. Understanding this axis is vital, as it offers insights into mechanisms that sustain NK cell activity and those that lead to functional exhaustion, thereby informing strategies to enhance therapeutic efficacy. A central challenge in NK cell immunotherapy is balancing cellular persistence with functional exhaustion. Persistent NK cell activity is desirable for sustained tumor control; however, prolonged activation often results in cellular exhaustion characterized by diminished cytotoxicity and cytokine production. This paradox hampers the long-term success of NK cell-based treatments. The CREM–IL-15 axis plays a complex role in this dynamic, potentially promoting NK cell survival and persistence while also contributing to exhaustion under certain conditions. Deciphering the molecular underpinnings of this paradox is essential for developing interventions that maintain NK cell functionality over time, thereby improving therapeutic outcomes in cancer patients.

Read PDF

Similar papers

Review Open access Sep 2026

Antigen-experienced NK-T cells: integrating new insights and exploring therapeutic potential in cancer immunotherapy

Conventional CD8+ T cells can acquire natural killer (NK) cell receptors upon persistent antigen exposure, forming antigen-experienced NK-T (AENK-T) cells. Their dual-state plasticity within the tumor immune microenvironment determines cancer immunotherapy outcomes. This narrative review synthesizes recent transcriptom...

Shunichiro Kuramitsu, Masasuke Ohno, Mitsugu Fujita · 0 citations
Sep 2026

NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor.

Natural killer (NK) cells constitute the first line of human immune defense. They have attracted extensive research in the field of tumor immunity owing to their potent cytotoxicity, robust cytokine secretion, and immunomodulatory capacity. However, chronic tumor antigen exposure would induce exhaustion in NK cells (NK...

Zi-Xuan Gou, Yu-Tong Bao, Li-Hong Liu et al. · 0 citations
Review Open access Aug 2026

Targeting immune checkpoint B7-H6 in cancer immunotherapy

Current findings position B7-H6 as a promising immuno-oncologic target at the intersection of immune surveillance, immune escape, and malignant progression, warranting continued investigation as a next-generation therapeutic axis in cancer immunotherapy.

Ziyi Yang, Qi Zhao · 0 citations
Sep 2026

Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks.

Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform t...

Mubin Tarannum, K. Dinh, Mila Stanojevic et al. · 0 citations
Review 2026

[Development of memory-like CAR-NK cells with durable antitumor activity].

How genetic modulation of NK-cell differentiation pathways may contribute to the establishment of next-generation CAR-NK cell therapies with improved durability and antitumor efficacy is discussed.

Takahiro Nakashima, Yuki Kagoya · 0 citations
Review Open access Sep 2026

IL-10’s contextual role in cytotoxic antitumor immunity: evidence, controversies, and therapeutic translation

Interleukin-10 (IL-10) is classically defined as a potent anti-inflammatory cytokine that protects tissues by constraining myeloid activation and limiting inflammatory cytokine production. Yet, accumulating evidence indicates that, in defined contexts, IL-10 can also promote antitumor immunity by enhancing the fitness...

Min-Chuan Zhang, Qi-Jing Li, Kong-Peng Lam et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.